Loading…
Employees: 1,723
Size HK inno.N (195940.KS) is a South Korea Health Care company (Medical/Nursing Services) with a market value of $745M, the 277th largest of 495 South Korea companies the cockpit tracks. Shares closed at ₩35,700 on 6 Nov 2026.
Performance Over six months the shares fell 31.9%, against +1.3% for the median peer and -24.5% for the South Korea market (cap-weighted) — 2nd lowest of 20 in its peer set.
Growth Revenue grew 7.1% over the last twelve months (peer median +6.9%); the operating margin is 11.9% (peer median 7.2%).
Valuation It trades at 11.8× forward earnings against a peer median of 24.0× (5th cheapest of 16).
Price implies For today's price to make sense, revenue must grow about -11% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -23 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 1.9 points above its cost of capital (5.2% WACC).
Next results Next results expected around 16 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩1.08T | ₩1.06T | ₩897B | ₩829B | ₩847B |
| Revenue growth | — | +19% | +8% | -2% | — |
| Gross profit | n/a | ₩472B | ₩414B | ₩355B | ₩333B |
| EBITDA | n/a | ₩156B | ₩130B | ₩101B | ₩87.1B |
| Net income | ₩86.9B | ₩75.7B | ₩61.6B | ₩47.2B | ₩38.1B |
| Free cash flow | n/a | ₩73.2B | -₩25.9B | ₩32.4B | ₩26.7B |
| Capital expenditure | n/a | ₩86.3B | ₩126B | ₩39.1B | ₩22.9B |
| Total debt | n/a | ₩522B | ₩439B | ₩451B | ₩457B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 195940.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.4% | -1.1% | 4th lowest of 21 |
| 6-month return | -31.9% | +1.3% | 2nd lowest of 20 |
| Distance from 52-week high | -39.1% | -21.4% | 3rd lowest of 21 |
| Revenue growth (TTM) | +7.1% | +6.9% | 10th highest of 21 |
| Operating margin | 11.9% | 7.2% | 7th highest of 21 |
| Forward P/E | 11.8× | 24.0× | 5th cheapest of 16 |
| Growth the price implies (Req g, 7 yrs) | -10.8% | 11.9% | 3rd least demanding of 17 |
| Growth delivered (Del g) | +12.2% | +11.6% | 9th highest of 17 |
| Hurdle (Req g minus delivered) | -23.0 pp | -0.3 pp | 3rd least demanding of 17 |
| ROIC minus cost of capital | +1.9 pp | -2.4 pp | 8th highest of 20 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HK inno.N 195940.KS | South Korea | $745M | -32% | +7% | 12% | 11.8× | -10.8% | +12.2% |
| WELL Health Technologies WELL.TO | Canada | $760M | -5% | +39% | 7% | 14.7× | 9.1% | +94.5% |
| Ginkgo Bioworks DNA | United States | $760M | +26% | -52% | -258% | n/a | n/a | n/a |
| Jinxin Fertility 1951.HK | Hong Kong | $800M | -2% | +7% | 11% | 24.4× | 18.0% | +12.4% |
| GMR Solutions GMRS | United States | $672M | n/a | -4% | 14% | 8.0× | -20.0% | -4.0% |
| Thyrocare Technologies THYROCARE.NS | India | $830M | +5% | +22% | 26% | 35.2× | 27.9% | +10.9% |
| Fulgent Genetics FLGT | United States | $653M | +49% | +7% | -36% | n/a | n/a | n/a |
| Nephrocare Health Services NEPHROPLUS.NS | India | $639M | +10% | +33% | 14% | 41.9× | 35.7% | +31.6% |
| Terveystalo Oy TTALO.HE | Finland | $883M | -19% | -8% | 8% | 11.1× | -4.6% | +5.3% |
| BML 4694.T | Japan | $887M | -2% | +4% | 7% | 18.6× | -9.7% | +1.6% |
| Shanghai Labway Clinical Laboratory 301060.SZ | China | $593M | -4% | -19% | 6% | n/a | 8.8% | +3.2% |
| AdaptHealth AHCO | United States | $1.00B | +8% | -3% | 3% | n/a | 16.3% | +25.2% |
| Regis Healthcare REG.AX | Australia | $1.05B | -17% | +17% | 4% | 25.1× | 14.6% | +14.4% |
| Strata Critical Medical SRTA | United States | $497M | 0% | +23% | -4% | 67.4× | n/a | n/a |
| JS Link 127120.KS | South Korea | $481M | -57% | +51% | -76% | n/a | n/a | n/a |
| Novogene 688315.SS | China | $1.16B | +31% | +6% | 7% | 35.7× | 17.1% | +8.2% |
| GoodRx GDRX | United States | $1.20B | +20% | -2% | 12% | 10.4× | 6.8% | +7.7% |
| Integral Diagnostics IDX.AX | Australia | $450M | -21% | +26% | 9% | 15.5× | 8.3% | +17.7% |
| Nutex Health NUTX | United States | $1.24B | +32% | +7% | 43% | 7.2× | -19.5% | +253.5% |
| Metropolis Healthcare METROPOLIS.NS | India | $1.25B | +12% | +20% | 18% | 45.6× | 32.4% | +10.5% |
| Pennant PNTG | United States | $1.27B | +1% | +38% | 6% | 24.0× | 21.1% | +19.4% |